Protease nexin I immunostaining in alzheimer's disease
β Scribed by Dr Dorrie E. Rosenblatt; Changiz Geula; M-Marsel Mesulam
- Publisher
- John Wiley and Sons
- Year
- 1989
- Tongue
- English
- Weight
- 821 KB
- Volume
- 26
- Category
- Article
- ISSN
- 0364-5134
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract __Alzheimer's disease afflicts every tenth human aged over 65. Despite the dramatic progress that has been made in understanding the disease, the exact cause of Alzheimer's disease is still unknown. Most gene mutations associated with Alzheimer's disease point at the same culprits: amyl
## Abstract Ramon y Cajal proclaimed in 1928 that βonce development was ended, the founts of growth and regeneration of the axons and dendrites dried up irrevocably. In the adult centers the nerve paths are something fixed, ended and immutable. Everything must die, nothing may be regenerated. It is
Tetrahydroaminoacridine (THA), a centrally acting anticholinesterase, was used in a two-month, double-blind, placebo-controlled crossover trial to treat 10 patients meeting DSM-111-R criteria for dementia of the Alzheimer type. Eight patients continued to take THA for a further three months. Nausea
## Discussion To date, the mechanism underlying drug-induced hyponatremia remains poorly understood. While some authors have suggested that the phenomenon may be a class effect of the SSRIs (Ball and Herzberg, 1994), others have cautioned that hyponatremia may develop with virtually any antidepres